Reversing tumor immunosuppression with next-gen GPCR modulation
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Reversing tumor immunosuppression with next-gen GPCR modulation
-
Narrado por:
-
De:
Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.
We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.
We’ll also be taking a look at the broader oncology landscape—what’s hot, who’s investing big, and where the biggest opportunities and challenges lie.
01:09 – Meet Sean Macdonald
05:40 – Kainova's GPCR platform and therapeutic focus
08:57 – The story and meaning behind the Kainova rebrand
10:25 – Series B funding and pipeline programs
16:43 – Exciting trends and innovations in oncology
29:17 – Upcoming milestones and future plans
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
- GPCR therapies: Eight promising biotechs hacking the cell signaling pathway
- Episode 182: Building a smart oncology pipeline with Cumulus Oncology
- Episode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics